Literature DB >> 11083304

Intrathecal baclofen pump use for spasticity: a clinical survey.

L Stempien1, T Tsai.   

Abstract

OBJECTIVE: To obtain information from continuous intrathecal baclofen infusion (CIBI) pump centers regarding specific clinical practices and experiences.
METHODS: A total of 115 centers were surveyed by mail.
RESULTS: Forty centers (35%) responded with information about 1,002 test doses and 936 pump placements. Patient diagnoses included cerebral palsy, spinal cord injury, traumatic brain injury, and others. The average test dose was 50 microg. A total of 87% of trials were successful. The most common test dose complications were nausea/vomiting (2.6%) and sedation (2.2%). Pump placement complications included cerebrospinal fluid (CSF) collection (3.3%), constipation (2.9%), headache (2.4%), and CSF leak (2.2%). The most common long-term complications were catheter kink or migration (4%) and infection (1.2%). Improved daily activities including easier diapering, dressing, transfers, orthotic wear and comfort, and sitting tolerance were reported in the majority (>90%) of patients. Mixed results were reported for oral motor function and head, bladder, and bowel control.
CONCLUSIONS: CIBI is an effective treatment for severe spasticity, with dramatic quality-of-life improvements and a small number of significant complications. Long-term benefits and complications need to be monitored in this complex population.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11083304     DOI: 10.1097/00002060-200011000-00010

Source DB:  PubMed          Journal:  Am J Phys Med Rehabil        ISSN: 0894-9115            Impact factor:   2.159


  19 in total

1.  Intrathecal baclofen therapy for spasticity of cerebral origin--does the position of the intrathecal catheter matter?

Authors:  Gnanamurthy Sivakumar; Yoong Yap; Mekidm Tsegaye; Michael Vloeberghs
Journal:  Childs Nerv Syst       Date:  2010-03-20       Impact factor: 1.475

Review 2.  Imaging evaluation of intrathecal baclofen pump-catheter systems.

Authors:  A C Miracle; M A Fox; R N Ayyangar; A Vyas; S K Mukherji; D J Quint
Journal:  AJNR Am J Neuroradiol       Date:  2010-10-28       Impact factor: 3.825

3.  Management of intrathecal baclofen therapy for severe acquired brain injury: consensus and recommendations for good clinical practice.

Authors:  Antonio De Tanti; Federico Scarponi; Michele Bertoni; Giulio Gasperini; Bernardo Lanzillo; Franco Molteni; Federico Posteraro; Dino Francesco Vitale; Mauro Zanpolini
Journal:  Neurol Sci       Date:  2017-05-06       Impact factor: 3.307

4.  Procedural safety of a fully implantable intravenous prostanoid pump for pulmonary hypertension.

Authors:  Manuel J Richter; Ralf Ewert; Christian Warnke; Henning Gall; Simon Classen; Friedrich Grimminger; Eckhard Mayer; Werner Seeger; Hossein-Ardeschir Ghofrani
Journal:  Clin Res Cardiol       Date:  2016-09-26       Impact factor: 5.460

5.  Characterization and restoration of altered inhibitory and excitatory control of micturition reflex in experimental autoimmune encephalomyelitis in rats.

Authors:  Jean-Rodolphe Vignes; Mathilde S A Deloire; Klaus G Petry; Frédéric Nagy
Journal:  J Physiol       Date:  2006-10-26       Impact factor: 5.182

6.  A Review of Spasticity Treatments: Pharmacological and Interventional Approaches.

Authors:  Eric Chang; Nilasha Ghosh; Daniel Yanni; Sujin Lee; Daniela Alexandru; Tahseen Mozaffar
Journal:  Crit Rev Phys Rehabil Med       Date:  2013

7.  Baclofen pump pocket infection: a case report of successful salvage with muscle flap.

Authors:  Bishara S Atiyeh; Shady N Hayek; Ghassan S Skaf; Ali Al Araj; Roukoz B Chamoun
Journal:  Int Wound J       Date:  2006-03       Impact factor: 3.315

8.  Reduction of spinal sensory transmission by facilitation of 5-HT1B/D receptors in noninjured and spinal cord-injured humans.

Authors:  Jessica M D'Amico; Yaqing Li; David J Bennett; Monica A Gorassini
Journal:  J Neurophysiol       Date:  2012-12-05       Impact factor: 2.714

9.  Constitutively active 5-HT2/α1 receptors facilitate muscle spasms after human spinal cord injury.

Authors:  Jessica M D'Amico; Katherine C Murray; Yaqing Li; K Ming Chan; Mark G Finlay; David J Bennett; Monica A Gorassini
Journal:  J Neurophysiol       Date:  2012-12-05       Impact factor: 2.714

Review 10.  A benefit-risk assessment of baclofen in severe spinal spasticity.

Authors:  Alessandro Dario; Giustino Tomei
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.